Life sciences companies are widely failing to maximise opportunities to automate the capture of adverse event data, according to a new study involving pharmaceutical organisations in the UK and US. The research reveals that pharmacovigilance (PV) automation plans are less advanced than they may first appear. Dr. John Price at Arriello, analyses the research findings.